VBI Vaccines (VBIV) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

VBI Vaccines is a biopharmaceutical company founded on an innovative eVLP technology platform designed to elicit potent and broad immune responses. Its historical achievement was the U.S. approval and commercialization of PreHevbrio, a three-antigen hepatitis B vaccine, but the company has since ceased commercial operations and entered restructuring proceedings under the CCAA in Canada. Its current strategy is to preserve capital, review strategic alternatives, and advance its most promising clinical-stage assets in cytomegalovirus (CMV) prevention and glioblastoma (GBM) treatment through this period of financial distress.

OncologyInfectious Diseases

Technology Platform

Proprietary enveloped Virus-Like Particle (eVLP) platform engineered to present multiple, properly folded antigens on a lipid membrane, mimicking natural pathogens to elicit potent and broad immune responses.

Opportunities

The eVLP platform holds promise for difficult vaccine targets like CMV, where there is a massive unmet need and no approved vaccine.

In oncology, VBI-1901 targets recurrent glioblastoma, an aggressive cancer with very few treatment options, representing a high-value niche if clinical efficacy is proven.

Risk Factors

The company is undergoing financial restructuring (CCAA) and has ceased commercial operations, posing an existential risk.

Its clinical programs require significant capital to advance, which is currently unavailable, and it faces intense competition in both its infectious disease and oncology focus areas.

Competitive Landscape

In CMV, VBI faces well-funded late-stage competitors from Merck and Moderna. In glioblastoma, the competitive landscape includes other immunotherapies and standard care, though effective options remain limited. The company's financial distress places it at a severe disadvantage against larger, solvent rivals.

More companies in Biologics / Biosimilars →More companies in United States →